Nitec's Lodotra works in late-stage arthritis study
ZURICH, Sept 2
ZURICH, Sept 2 (Reuters) - Privately owned Swiss biotech firm Nitech said its Lodotra drug proved effective in a late-stage trial of patients with rheumatoid arthritis and it will use the data to apply for U.S. approval.
Lodotra, which is partnered with Merck KGaA (MRCG.DE) in Germany and Austria, was more effective against inflammation of joints than a placebo in the 350-patient study, Nitec said.
Mundipharma has distribution rights for Lodotra in the rest of Europe and Nitec retains all commercialisation rights for the United States and rest of the world.
(Reporting by Sam Cage; editing by John Stonestreet)
- Pope attacks mega-salaries and wealth gap in peace message
- Air strike kills 15 civilians in Yemen by mistake: officials
- Probation for drunk Texas teen driver who killed four sparks backlash
- Atheists face death in 13 countries, global discrimination: study
- South Africa admits error over 'schizophrenic' Mandela signer |